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Background: The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation
and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the
therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study was an
observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar
epoetins for the treatment of chemotherapy-induced anaemia (CIA) in the clinical setting.
Methods: Patients >18 years with CIA (haemoglobin [Hb] <11 g/dL) in association with solid tumours, lymphoma or
myeloma and eligible for treatment with an epoetin biosimilar were included in this study. Patient characteristics were
recorded at baseline along with anaemia-related information, such as observed and target Hb (as chosen by the
treating clinician), brand and dose of epoetin biosimilar prescribed, and details of any other treatments. Patients were
then followed-up at 3 and 6 months. The primary endpoint was Hb response (defined as Hb reaching ≥10 g/dL, an
increase of Hb ≥1 g/dL since inclusion visit or reaching physician-defined target Hb, with no blood transfusions in the
3 weeks prior to measurement). Other endpoints included adverse events, achievement of target Hb and associated
treatments.
Results: Overall, 2333 patients >18 years (mean age 66.5 years) with CIA (haemoglobin [Hb] <11 g/dL) in association
with solid tumours, lymphoma or myeloma and eligible for biosimilar epoetin treatment were included. 99.9% of
patients received epoetin zeta (median dose 30,000 IU/week). Mean baseline Hb was 9.61 g/dL, with 35.6% of patients
having moderate anaemia (Hb 8–9.5 g/dL). Hb response was achieved in 81.6% and 86.5% of patients at 3 and
6 months, respectively. Overall mean change in Hb level was 1.52 ± 1.61 and 1.72 ± 1.61 g/dL at 3 and 6 months,
respectively. Transfusion and thromboembolic event rates were 9.4% and 2.4% at 3 months, and 5.8% and 1.5% at
6 months, respectively.
Conclusions: Epoetin zeta was effective and well tolerated in the management of CIA in patients with solid tumours,
lymphoma and myeloma.
Trial registration: Trial registration number: NCT02140736 (date of registration: 14 May 2014).
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Supportive therapy for patients undergoing chemotherapy
can be of great benefit in alleviating undesirable conse-
quences of this specific treatment. One such consequence
is chemotherapy-induced anaemia (CIA), a common com-
plication of myelosuppressive chemotherapy across a large
range of cancer types. According to the European Cancer
Anaemia Survey (ECAS), 67.0% of cancer patients were
anaemic (haemoglobin [Hb] levels of <12 g/dL) during a
6-month period [1]. Patients presenting with CIA often
suffer from fatigue and impaired quality of life (QoL) [2].
Successful Hb response through supportive therapy has
been demonstrated to improve fatigue and QoL signifi-
cantly in patients with CIA [2]. CIA is also independ-
ently associated with reduced survival rates for patients
with solid tumours, lymphoma or myeloma [3], further
highlighting the importance of providing appropriate
supportive care.
Currently, anaemia treatment may involve red blood
cell (RBC) transfusions, iron supplementation (in absolute
or functionally iron-deficient anaemia) and erythropoiesis-
stimulating agents (ESAs) [4]. RBC transfusions can pro-
vide a rapid, transient increase in Hb; however, as repeated
transfusions are required to maintain Hb levels, this treat-
ment is usually reserved for more severe cases of anaemia
[5]. Furthermore, transfusions continue to be associated
with risk of transfusion reactions or infections [6]. A sys-
tematic study of 125,223 patients undergoing major gen-
eral surgery showed that transfusions were associated with
a significantly (P < 0.05) increased risk of mortality, com-
posite morbidity, pneumonia and sepsis [7]. These results
were further demonstrated in a long-term review of 10,289
patients for up to 10 years post-coronary artery bypass
surgery, in which RBC transfusion was associated with
significant reductions in early (up to 6 months) and late
(up to 10 years) survival when controlling for demo-
graphics, comorbidities, operative factors and early haz-
ard for death [8].
ESAs are biological analogues of human erythropoietin
produced in cell lines using recombinant DNA technology
[9]. The major goals of ESA use are sustained correction
of anaemia and resultant improvement in QoL for pa-
tients, while also reducing the need for RBC transfusions
[4]. The first ESA was epoetin alfa; second and third gen-
eration ESAs have since been developed with a longer
half-life than first-generation ESAs [10,11]. The impact of
ESAs on overall patient survival and mortality in anaemia
associated with cancer has been the subject of several tri-
als and meta-analyses [12]. A large meta-analysis of 13,933
patients in 53 trials indicated that use of ESAs led to a re-
duction in survival and increased mortality in patients
with cancer, with the authors recommending that the ob-
served risks be measured against the benefits of ESA treat-
ment [13]. However, while it cannot be ruled out, thesame risk has yet to be confirmed in patients receiving
chemotherapy [12].
Since the patent expiry of epoetin alfa, several biosimilar
epoetins have become available [14]. Biosimilars, as de-
fined by EU legislation, are therapeutic proteins exhibiting
comparable quality, and non-clinical and clinical similarity
to an existing reference biological medicine whose patent
has expired. These biosimilars have undergone a rigorous
preclinical, clinical and post-approval process to ensure
that the mode of action, efficacy and safety are equivalent
to originator products [15]. As part of this process, the
Committee for Medicinal Products for Human Use
(CHMP) recommends continuing post-approval studies
of biosimilars to evaluate safety [16]. Once a product has
been approved, such studies form part of an ongoing risk
management plan through collection of real-life clinical
evidence.
The present study, ORHEO (biOsimilaRs in the manage-
ment of anaemia secondary to chemotherapy in HaEma-
tology and Oncology), was a post-marketing study aimed
at observing Hb response in CIA patients presenting
with various solid tumours, lymphoma or myeloma
when treated with biosimilar epoetin alfa.
Methods
Study design
This was an observational, non-interventional, longitudinal,
national, multicentre study (NCT02140736). After screen-
ing for inclusion and exclusion criteria, patients were en-
rolled in the study and followed-up for 6 months over
three visits: inclusion visit (D0), 3-month follow-up visit
(M3) and 6-month end-of-study visit (M6). The study
protocol was reviewed and approved by the ethics commit-
tee (Advisory Committee on Information Processing Re-
search in the Field of Health [Comité consultatif sur le
traitement de l'information en matière de recherche dans le
domaine de la santé], Ministry of Higher Education and
Research, INSERM 700, Faculty of Medicine, Paris, France).
Results were recorded on case report forms. As this is a
post-approval, observational, non-interventional study only
verbal consent was obtained in compliance with French
law for such studies. Informed patient consent was ob-
tained verbally prior to participation in the study and writ-
ten consent was signed by the physician.
Patients
Inclusion criteria included patients at least 18 years of age
presenting with CIA (irrespective of chemotherapy cycle)
associated with solid tumours, lymphomas or myelomas
and eligible for treatment with an epoetin alfa biosimilar.
Exclusion criteria included absence of chemotherapy
treatment, presence of any contraindications for epoetin,
hypersensitivity to any of the treatment components, previ-
ously confirmed pure red cell aplasia (PRCA), uncontrolled
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or involvement in another biosimilar epoetin study.
Primary and secondary objectives
The primary objective of the study was to observe response
to treatment with an epoetin alfa biosimilar in patients pre-
senting CIA in association with solid tumours, lymphoma
or myeloma.
Secondary objectives included changes in biological in-
dicators such as Hb, haematocrit, reticulocytes, serum
iron, ferritin and blood pressure; disease outcome and the
safety profile of epoetin alfa biosimilars. CIA was defined
according to the World Health Organization (WHO) cri-
teria [17], measured prior to starting treatment. A patient
was described as a ‘responder’ to treatment with an epoe-
tin biosimilar if Hb levels were at least equal to 10 g/dL; if
there had been an increase in Hb levels of at least 1 g/dL
since the inclusion visit; or if Hb level reached target level
set by the physician on D0, without any blood transfusions
in the 3 weeks prior to measurement (transfusion details
were reported by investigators). In patients with base-
line Hb levels at least equal to 10 g/dL, only those who
reached their Hb target or had an Hb increase >1 g/dL
were regarded as responders. Disease outcomes were re-
ported using the WHO performance score [18].
Statistical methodology
All statistical analyses were performed on the per protocol
population. This excluded patients with missing baselineFigure 1 ORHEO study consort diagram.Hb values, patients for whom age was not recorded, pa-
tients who had not initiated chemotherapy at baseline, pa-
tients who were not receiving an epoetin biosimilar at
baseline and patients who switched to another epoetin
treatment between baseline and Month 6. In addition, pa-
tients with a disease other than those described in the
protocol were excluded. The rates of Hb responders were
calculated at each visit with 95% confidence intervals, as
well as logistic regressions for prognostic factors of Hb re-
sponse, using SAS® software (9.2 release).
Results
Patient characteristics at baseline
A total of 2333 patients were included in the study
(attended clinic at least once) from 235 investigational cen-
tres (see Figure 1). The rate of metastasis was 71.68% in
the patient population with solid tumours. The main rea-
sons for early withdrawal from the study were death of the
patient (66.93%) followed by loss of contact (16.46%). All
deaths were considered unrelated to treatment with epoe-
tin biosimilars. Only 4.08% of patients withdrew early due
to a change of ESA.
Demographic data are shown in Table 1. The mean base-
line Hb level was 9.61 g/dL, across all patients. At baseline,
57.92% of patients had grade 1 anaemia (9.5–11 g/dL) and
35.58% of patients had grade 2 anaemia (8–9.5 g/dL). Tar-
get levels of 12–12.9 g/dL were set for 51.10 of patients
and 10–11.9 g/dL set for 39.57% of patients. Overall,
16.75% of patients had at least one transfusion during
Table 1 Patient demographics
Characteristic Value
Age, mean ± SD (years) 66.49 ± 11.77
Patients with solid tumours, mean (years) 65.76
Patients with lymphoma, mean (years) 68.59
Patients with myeloma, mean (years) 70.65
Female (%) 7
Male (%) 3
Hb, mean ± SD (g/dL) 9.59 ± 0.88
sBP, mean ± SD (mmHg) 125.75 ± 14.48
dBP, mean ± SD (mmHg) 74.18 ± 9.79
Malignancies, n (%) 2310 (100)
Solid tumours, n (%) 1838 (79.57)
Lymphoma, n (%) 301 (13.03)
Myeloma, n (%) 171 (7.40)
Height, mean ± SD (cm) 166.35 ± 8.72
Weight, mean ± SD (kg) 67.46 ± 14.23
BMI, mean ± SD (kg/m2) 24.33 ± 4.62
BMI, body mass index; dBP, diastolic blood pressure; Hb, haemoglobin; sBP,
systolic blood pressure; SD, standard deviation.
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patients started their treatment with a biosimilar epoetin
after inclusion, 3.90% of patients were already being
treated with an epoetin biosimilar before inclusion, and
the remainder began treatment on the date of inclusion.
Biosimilar epoetin treatment
Almost all (99.9%) patients received the biosimilar
Retacrit® (epoetin zeta, Hospira); the remaining three
patients received Binocrit® (epoetin alfa, Sandoz). The
median dose of biosimilar epoetin was 30,000 IU/week
during the course of the study. Most patients (99.7%)
received biosimilar epoetin via the subcutaneous route
and almost all (97.97%) received single weekly biosimilar
epoetin injections.
Hb response
At M3, 81.6% (95% CI 79.91–83.26) of patients had res-
ponded to treatment compared to 86.5% at M6 across all
disease categories (95% CI 84.80–88.10 [see Figure 2a]).
The proportion of responders for patients with haemato-
logical malignancies (lymphoma and myeloma) and solid
tumours were similar. Furthermore, the proportion of re-
sponders for two of the most commonly reported solid tu-
mours was similar to the total study population. Of the
patients with breast cancer, 86.80% (95% CI 82.01 –90.48)
and 91.67% (95% CI 87.29–94.66) had responded to treat-
ment at M3 and M6, respectively. Similarly, of the patients
with lung cancer, 76.68% (95% CI 72.12–80.69) and 86.04%
(95% CI 81.32–89.73) had responded to treatment at M3and M6, respectively (see Figure 2b). Mean time to
achievement of target Hb was 80.1 days for the re-
sponder population.
Overall, the mean change in Hb from inclusion to M3
was 1.52 ± 1.61 g/dL, compared to 1.72 ± 1.61 g/dL at M6
(See Figure 3a). An increase in Hb level of >2 g/dL was
observed in 37% of patients at M3 and 44.2% of patients
at M6. An increase in Hb of 1–2 g/dL was observed in
27.3% and 24.5% of patients at M3 and M6, respectively.
Figure 3b shows the change in Hb level at M6, stratified
by Hb level at study inclusion. Results were also analysed
by disease type. In the solid tumour group, mean Hb levels
increased by 1.44 g/dL and 1.65 g/dL at M3 and M6, re-
spectively. In the lymphoma group, mean Hb increased by
1.72 g/dL and 2.12 g/dL at M3 and M6, respectively, while
in the myeloma group, mean Hb increased by 2.03 g/dL
and 1.57 g/dL, respectively. Where transfusion data were
available, transfusion rates were 9.4% and 5.8% at M3 and
M6, respectively for the total study population. Transfu-
sion rates were 9.7% and 5.0% at M3 and M6, respectively
for patients with solid tumours, 9.4% at both M3 and M6
for patients with lymphoma and 6.9% at both M3 and M6
for patients with myeloma.
Between inclusion and M6, a total of 1202 patients
discontinued epoetin treatment. Of patients that dis-
continued, 39.5% of stops were due to satisfactory Hb
being met, 26.6% were due to stopping or changing
chemotherapy treatment, 14.9% were due to satisfactory
Hb being reached and cessation of chemotherapy, 10.8%
were due to inefficacy and 1.9% stopped due to an ad-
verse effect.Clinical parameters
Haematocrit, reticulocyte, iron, ferritin and blood pressure
readings did not differ significantly at D0, M3 and M6 (see
Table 2). A large standard deviation was observed in reticu-
locyte count. This could be explained by fluctuation in cell
numbers as a result of chemotherapy cycles. Blood pressure
was consistent across D0 (mean sBP: 125.75 mmHg, mean
dBP: 74.18 mmHg), M3 (mean sBP: 125.58 mmHg, mean
dBP: 74.51 mmHg) and M6 (mean sBP: 126.04 mmHg,
mean dBP: 74.33 mmHg).Safety
Overall, 17.1% of patients experienced at least one
clinically significant adverse event (see Table 3). The
rate of thromboembolic events was 2.4% and 1.5% at
3 and 6 months, respectively. During the course of
the study, 12% of patients were treated with an anti-
thrombotic agent (lymphoma: 9.3%; myeloma: 33.3%;
solid tumour: 10.4%). A rise in blood pressure was re-
ported in 1.3% of patients at M3. The same rate was
reported at M6.
Figure 2 Treatment response stratified (a) by disease category and (b) by the most commonly reported solid tumours.
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At D0 73% of patients had a performance status of 0 or
1, compared with 68.3 and 69.7% of patients at M3 and
M6, respectively (see Figure 4a).
Clinical progress was recorded as either ‘exacerbation’,
‘stable’ or ‘improvement’. Improvement was seen in 40.20%
and 40.38% of patients at M3 and M6, respectively (see
Figure 4b).
Associated treatments
Associated treatments included antithrombotic agents
(12% overall), IV iron (10.3% overall), oral iron (16.3%),
folates (6.6% overall), vitamin B (4.3% overall) with a
small proportion taking other vitamins (1.6% overall). A
further 17.1% of patients were reported as being on
‘other treatments’.
Discussion
Anaemia is a common complication of chemotherapy
treatment. The advent of ESAs has led to a reduction in
transfusion requirements, improved QoL and reduced fa-
tigue for patients with CIA [2]. An important limitation ofESAs and biological medicines in general remains the high
cost, which may limit access in some countries [19]. EU-
approved biosimilar medicines can offer physicians the re-
assurance of rigorous comparability studies and extensive
clinical and post-marketing surveillance programmes, in
addition to cost savings due to lower development costs.
Post-approval studies are an important aspect of post-
approval efficacy and safety assessment of biosimilar med-
icines. This study forms part of an ongoing surveillance
programme for epoetin zeta, a biosimilar of epoetin alfa.
The primary objective of this observational study was to
record the rate of response to treatment of CIA with bio-
similar epoetins in the oncology and onco-haematology
settings. The definitions of Hb response utilised herein re-
flect the nature of this study, as it not only includes
achieving target Hb but also clinically significant increases
in Hb (achievement of 10 g/dL, or an increase in 1 g/dL
from inclusion). The results of this study contribute to the
growing body of evidence regarding the efficacy and safety
of epoetin biosimilars in oncology.
The efficacy results reported herein correlate closely
with previous research on epoetin zeta. A phase III
Figure 3 Mean change (a) from baseline in haemoglobin level in total study population and (b) change after six months stratified by
baseline haemoglobin level.
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period reported a mean Hb increase of 1.8 g/dL in the
intention-to-treat (ITT) population, with 81.5% of patients
achieving ≥1 g/dL Hb increase [20], both outcomes being
similar to the findings here. This was the first open-labelTable 2 Secondary outcomes
D0 (n)
Haematocrit (%) 29.54 ± 4.12 (2158)
Reticulocytes (/mm3) 53083.10 ± 43772.32 (330)
Iron (μg/100 mL) 94.96 ± 129.22 (546)
Ferritin (ng/mL) 510.55 ± 629.61 (555)
sBP (mmHg) 125.75 ± 14.48 (1934)
dBP (mmHg) 74.18 ± 9.79 (1930)
dBP, diastolic blood pressure; sBP, systolic blood pressure.study on biosimilars conducted in Europe, and while more
are currently planned or underway, ORHEO remains the
largest with regard to patient numbers. Mean Hb response
reported in the current study is similar to that reported for
epoetin alfa in CIA associated with multiple myeloma [21].M3 (n) M6 (n)
34.41 ± 5.78 (1839) 34.90 ± 6.03 (1419)
57478.34 ± 47391.55 (228) 52803.71 ± 52301.40 (146)
140.39 ± 152.77 (295) 144.98 ± 152.96 (182)
512.83 ± 801.58 (301) 390.82 ± 466.91 (214)
125.58 ± 15.80 (1675) 126.04 ± 15.41 (1353)
74.51 ± 10.31 (1675) 74.33 ± 10.02 (1351)
Table 3 Clinically significant adverse events
Solid tumours Lymphoma Myeloma Overall
Thromboembolic events (%) 3.74 1.10 5.0 3.49
Bleeding (%) 2.64 1.47 1.25 2.38
Infection (%) 4.23 8.82 6.88 5.04
Local intolerability (%) 0.06 0.37 0.63 0.15
Rise in blood pressure (%) 2.33 2.21 1.25 2.23
Other (%) 9.14 7.72 8.75 8.92
Michallet et al. BMC Cancer 2014, 14:503 Page 7 of 9
http://www.biomedcentral.com/1471-2407/14/503The rate of Hb response showed a reduction at M6 for
patients with myeloma compared to M3. Myeloma therapy
is associated with a relatively high risk of deep vein throm-
bosis, particularly in the case of thalidomide-anthracycline
regimens [22]. A possible reason for the reduction in Hb
response noted here could be the setting of more conser-
vative treatment targets due to thromboembolic risk asso-
ciated with myeloma chemotherapy and the disease itself.
No unexpected adverse events (AEs) were seen during
the course of this study. The overall rate of treatment-
related AEs was similar to that reported previously forFigure 4 Performance status (a) of all patients and (b) stratified by diepoetin zeta (10.4%). The rate of thromboembolic events
(3.55%) was lower than reported previously for epoetin
zeta (4.2%) [20] and epoetin alfa (4.0%). Patient death
was the main reason for discontinuing this study. No
deaths were considered related to treatment, and the
death rate in the current study can be attributed to the
characteristics of the population, particularly the high
rate of metastatic cancer at baseline.
As part of this study, WHO performance scale data and
disease progression were collected to give context to Hb
response rates reported. At baseline, 73.0% of patientssease category.
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1, compared to 68.3% at M3 and 69.7% at M6. Evidence
suggests Hb levels correlate with WHO performance sta-
tus [23], and while it is hard to distinguish changes due to
disease progression and changes due to improvement in
Hb, the number of patients with a WHO performance sta-
tus of 0 increased at both M3 and M6, indicating that
some patients felt more physically able upon completion
of the study. In terms of disease progression, an improve-
ment in disease state was considerably more common in
patients with a lymphoma, at M6 (60.9%). This could be
a result of the efficacy/safety profiles of treatments in
this group. Any improvement or exacerbation in disease
outcomes should not be considered related to epoetin
treatment. Such outcomes are confounded by patient
characteristics such as age and disease status, as well as
the nature of chemotherapy regimens, which vary con-
siderably, particularly in the case of the solid tumour
category.
This manuscript reports the results of an observational
study. It is therefore difficult to address potential con-
founding factors surrounding treatment. However, it is an-
ticipated that the ORHEO study can complement the
findings of controlled clinical trials through offering real-
life treatment observation. There was a significant dispar-
ity between the numbers of patients with solid tumours
compared to those with myeloma or lymphoma, which
corresponds well with the relative epidemiology of these
cancer types in Europe [24,25]. The definition of response
in this study relates to clinically meaningful change in Hb,
as befits the real-life setting and observational nature. As
such, the rate of response should not be compared with
that reported in randomised controlled clinical trials. One
important limitation in this study was the lack of repre-
sentation from biosimilar epoetins other than Retacrit.
This reflects availability at the centres involved during the
course of the study, and is not through deliberate omission
or inherent study design.
Given the negative impact anaemia has on the QoL and
overall survival in most cancer types [2,3], it is not surpris-
ing that European guidelines recommend ESA treatment
to correct CIA and reduce the need for transfusion [26].
Guidance from the EMA states that in patients with non-
myeloid malignancies treated with chemotherapy and an
Hb level of <10 g/dL, treatment with ESAs might be con-
sidered to increase Hb to ≤12 g/dL or to prevent further
decline in Hb. In patients treated with curative intent,
ESAs should be used with caution. Furthermore, the use of
ESAs should be carefully reconsidered in patients with a
high risk of thromboembolic events. ESAs have been of
great use to vast numbers of cancer patients receiving
chemotherapy and are associated with patient benefits such
as freedom from RBC transfusion and improvements in
QoL. However, biological medicines such as recombinantESAs are costly. The introduction of biosimilar medicines
has the potential to provide cost competition and reduce
cost to the payer due to their lower development costs
[27]. Indeed, a recent cost-efficiency study conducted in
France, Germany, Italy, Spain, and the UK compared va-
rious regimens of biosimilar and originator ESAs in the
management of CIA [19]. Biosimilar ESA therapy was con-
sistently cost-efficient over treatment with originator prod-
ucts under both fixed and weight-based dosing scenarios.
The cost benefits of biosimilar ESAs may therefore in-
crease patient access to this important form of treatment.
However, physicians should not be obliged to prescribe
biosimilars for purely cost reasons; only on proof of quality,
efficacy and safety should biosimilars be considered a vi-
able option. This study adds to the body of evidence sup-
porting the efficacy and safety of the biosimilar ESA
epoetin zeta in patients with CIA.
Conclusions
This study, the largest of its type, demonstrated a high
rate of response to epoetin zeta treatment in a large pa-
tient population with CIA. The rate of thromboembolic
events was lower than previously observed for this treat-
ment, while no unexpected treatment-related AEs were
identified.
Observational studies present a valuable means of asses-
sing efficacy and safety under clinical conditions and com-
plement the current body of data derived from randomised
controlled trials.
This study assessed the clinical profile of biosimilar
epoetin zeta as part of an ongoing commitment to post-
marketing observation, and demonstrated that epoetin
zeta is well-tolerated and efficacious in treating anaemia
in cancer patients with CIA.
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